Litigators of the Week: Counsel to the AndroGel defendants

Court dockets show little success for drugmakers in blocking direct purchasers from obtaining class certification in pay-for-delay cases. So defence counsel had particular reason to celebrate this week when a judge rejected class status for the pharmaceutical wholesalers seeking damages from reverse-payment settlements for Androgel.

Get unlimited access to all Global Competition Review content